Thirdly, although high expression of SLC16A3 is associated with poor clinical survival outcomes in cancer patients, it is still unclear how SLC16A3 affects patient clinical outcomes through the immune system and further research is needed. The gene discussed is SLC16A3; the disease is cancer.